Archive · 24 Jul 2025
Dr Reddy's Shares Rise Amid Mixed Brokerage Views
Imagine a company called Dr. Reddy's that makes medicines.
The company's stock price went up a bit recently!
Their profits also increased a little.
However, some people who watch the stock think things could be better because of some challenges, like less profit from certain medicines.
Other people are more optimistic, thinking the company will do well because of new medicines coming out.
Different financial experts have different opinions, with some saying to sell the stock and others saying to buy it.
Dr. Reddy's Laboratories (DRL) shares increased by 3% on Friday.
The stock reached Rs 1,287.90 on BSE, up from its previous close of Rs 1,247.55.
DRL's Q1 FY26 profit after tax (PAT) rose 2% year-over-year to Rs 1,417.8 crore.
Brokerage views on DRL are mixed, with some citing margin pressures.
JM Financial maintained a 'BUY' rating and a target price of Rs 1,521.
- Who
- Dr. Reddy's Laboratories Ltd (DRL)
- What
- Dr. Reddy's Laboratories shares increased in value.
- When
- Friday
- Where
- BSE
- Why
- Mixed views among brokerages post Q1 results.
Concerns and Negative Outlook
Optimistic Outlook
Brokerage Ratings
Concerns and Negative Outlook
HDFC Institutional Equities has a 'Reduce' rating due to margin pressures and price erosion in the US business.
Optimistic Outlook
JM Financial maintained a 'BUY' rating, seeing potential in upcoming generic GLP-1 launches.
- Stock Increase
- 3%
- Stock Price (BSE)
- Rs 1,287.90
- Previous Close
- Rs 1,247.55
- PAT Q1 FY26
- Rs 1,417.8 crore
- PAT YoY Increase
- 2%
- Brokerage Ratings
- Mixed (Reduce, Hold, BUY)